IEX •
Healthcare •
Biotechnology •
Quote as of 07/14/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization938.76 mln
Float23.66 mln
Earnings Date08/19/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
39
/ 100
Underperforming
Debt / Equity
0.09
Debt-free
ROE
-48.34
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Alto Neuroscience is a US-based drug development company focused on creating new treatments for psychiatric and neurological conditions, including depression, bipolar disorder, schizophrenia, and Parkinson's disease. The company currently has six experimental drugs at various stages of clinical testing, ranging from early safety studies to mid-stage trials evaluating how well each treatment works. Founded in 2019 and based in Mountain View, California, Alto Neuroscience aims to bring more precise and effective options to patients with conditions that remain difficult to treat with existing medicines.
